ALLK Berita Valas

Allakos Says Phase 3 Study Of Lirentelimab In EoD Missed Symptomatic Co-primary Goal

Biotechnology company Allakos Inc. (ALLK) on Friday reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (EoD).

RTTNews | 1084 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.16789	GBPUSD	1.35093	AUDUSD	0.653
USDJPY	146.942	USDCAD	1.37505	USDCHF	0.80183